Last reviewed · How we verify
0.33% ropivacaine 250ml
Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses.
Ropivacaine is a local anesthetic used primarily for regional anesthesia and pain management. It is less cardiotoxic than bupivacaine and has a longer duration of action compared to lidocaine. The 0.33% formulation in a 250ml solution is typically used for peripheral nerve blocks and epidural anesthesia. Due to its lower toxicity profile, it is often preferred in patients at higher risk of systemic toxicity. However, the product from Guangzhou General Hospital of Guangzhou Military Command does not have an FDA label, which may limit its use in certain markets.
At a glance
| Generic name | 0.33% ropivacaine 250ml |
|---|---|
| Sponsor | Guangzhou General Hospital of Guangzhou Military Command |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine works by reversibly binding to and blocking voltage-gated sodium channels in nerve cells, which prevents the generation and conduction of action potentials.
Approved indications
Common side effects
- Nausea
- Dizziness
- Headache
- Vomiting
- Back pain
Drug interactions
- Other local anesthetics
- Sedatives
Key clinical trials
- The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: